Continuous Glucose Monitors Overestimate Glycemic Responses
By Elana Gotkine HealthDay Reporter
THURSDAY, March 6, 2025 -- Continuous glucose monitoring (CGM) can overestimate glycemic responses, according to a study published online Feb. 26 in The American Journal of Clinical Nutrition.
Katie M. Hutchins, from the University of Bath in the United Kingdom, and colleagues examined glycemic responses to different test foods/beverages using CGM versus capillary sampling among 15 healthy female and male participants (nine and six, respectively). Participants completed seven laboratory visits in a randomized crossover design with washout of ≥48 hours between visits. At each visit, participants consumed an oral carbohydrate challenge composed of either 50 g glucose or equivalent carbohydrate as a whole-fruit, blended-fruit, or commercial fruit smoothie.
The researchers found that compared with capillary estimates, CGM-estimated fasting and postprandial glucose concentrations were 0.9±0.6 and 0.9±0.5 mmol/L higher, respectively. There was variation in CGM bias by postprandial test, with the glycemic index for commercial fruit smoothie higher with CGM than capillary (69 versus 53). There was variation by participant in the differences in CGM versus capillary fasting glucose concentrations. Time >7.8 mmol/L was overestimated by about fourfold with CGM in unadjusted analyses; this overestimate was reduced to about twofold after adjustment for baseline differences.
"These data demonstrate that a CGM can overestimate postprandial glycemia, and to differing degrees across foods/beverages," the authors write. "Therefore, if accurate quantification of postprandial glycemia is the primary aim, then capillary blood should be the preferred method and CGM may not be suitable, at least with respect to the CGM device tested in the present study."
Several authors disclosed ties to the pharmaceutical, nutrition, and other industries; the data were supported by an unrestricted grant from Innocent Drinks.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis
TUESDAY, May 13, 2025 -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.